19.05.2021 | Research Ins]i[ghts: Cardiac Safety Symposium 2021
Research Ins]i[ghts: Cardiac Safety Symposium 2021
Don't miss this 2-day interactive online event and Current Challenges in Safety Pharmacology and Cardiac Physiology, in-silico modelling and Best Practices and Evolvements of Safety Pharmacology Methods.
Date and time:
Start: Wednesday, May 19th (Beginning at 1PM CEST, 7AM EDT )
End: Thursday, May 20th (Beginning at 1PM CEST, 7AM EDT )
KEYNOTE PRESENTERS:
Yasunari Kanda, PhD, Division head, National Institute of Health Sciences Japan
Title: Current status and future perspectives in cardiac safety assessment using human iPSC technology
Day 1 [1:10 PM - 2 PM CEST]
Michael K. Pugsley, PhD, FBPhS, DSP (Cytokinetics)
Title: A 20 Year Journey through the Continuously Evolving Role of Safety Pharmacology in Drug Safety Evaluation
Day 2 [3:10 PM - 4 PM CEST]
Register Here
Access the full agenda of the Meeting below:
Agenda
(please note that additions may be made to this agenda as we appraoch the event)
Additional confirmed speakers:
Ralf Kettenhofen, PhD, Senior Scientist and Business Development, Fraunhofer Institute for Biomedical Engineering IBMT
Title: From iPSC Banking to Drug Development & Cardiac Safety
Day 1 [2 PM - 2:30 PM CEST]
Bettina Lickiss, PhD, Scientific Communications Manager, innoVitro GmbH
Title: Advanced cardiac contractility assessment with integrated mechanical and optical stimulation of human iPSC-derived cardiomyocytes
Day 1 [2:45 PM - 3:10 PM CEST]
Khuram Chaudhary, PhD, Scientific Director, GlaxoSmithKline
Title: In vitro cardiac safety pharmacology- considerations beyond hERG
Day 1 [3:10 PM - 3:35 PM CEST]
Ravi Vaidyanathan, PhD, Product Manager - Cardiac - FUJIFILM Cellular Dynamics, Inc.
Title: Predictive and Physiologically Relevant 3D Tri-culture Cardiac Microtissue with iCell® Cardiomyocytes, Endothelial Cells and Primary Cardiac Fibroblast
Day 1 [3:35 PM - 3:45 PM CEST]
Stephen Jenkinson, PhD, Director of In Vitro Pharmacology, Pfizer Inc.
Title: The use of stem cell cardiomyocyte models in predicting clinical cardiac endpoints
Day 1 [3:45 PM - 4:10 PM CEST]
Jin Chang, BD & Alliance Manager, NEXEL Co. Ltd
Title: Challenging our understanding of iPSC-based cardiac safety with physiologically relevant and assay-ready cell culture media
Day 1 [4:10 PM - 4:20 PM CEST]
Adam Hill, PhD, Head Computational Cardiology, Victor Chang Cardiac Research Institute
Title: An automated, cloud-based platform for quality control, data analysis and risk prediction of inherited and drug-induced arrhythmias
Day 2 [1:05 PM - 1:30 PM CEST]
Jessica Veenman-Koepke, Scientist & Project leader at Ncardia
Title: Multi-parametric Drug Safety Assessment in Bioreactor-produced Ncyte hiPSC-derived Cardiomyocytes
Day 2 [1:30 PM - 1:40 PM CEST]
Gary Mirams, Professor of Mathematical Physiology, University of Nottingham
Title: Examining temperature dependence of hERG1a gating
Day 2 [1:40 PM - 2:05 PM CEST]
Teun de Boer, Associate Professor, Dept. of Medical Physiology, UMC Utrecht
Title: Building hybrid biological-digital twins of cardiomyocytes using dynamic clamping
Day 2 [2:05 PM - 2:30 PM CEST]
James Kramer, Principal Scientist, Charles River Laboratories
Title: ICH S7B Q&As - Best Practices for Ion Channel Assays
Day 2 [2:45 PM - 3:10 PM CEST]
Al George, Professor and Chair of Pharmacology, Northwestern University
Title: Automated Patch Clamp to Assess Sodium Channel Blocker Effects on hiPSC-derived Cardiomyocytes
Day 2 [4:00 PM - 4:25 PM CEST]
